Bruce Klein, MD, was recently awarded $995,500 over 2 years from the National Institutes of Health-National Institute of Allergy and Infectious Diseases for his project, “Targeting hybrid histidine kinase for broad spectrum antifungal therapy.” This project was funded under the American Recovery and Reinvestment Act (ARRA) of 2009 and will support a project to address the public health need for the development of effective new anti-fungal drugs by seeking to identify, characterize and capitalize on a novel drug target in pathogenic fungi.
Dr. Bruce Klein, MD, also received an award of $297,000 over 2 years from the National Institutes of Health-National Institute of Allergy and Infectious Diseases as a supplement to his current project, “Mechanisms of Anti-fungal Vaccine Immunity.” These funds will support increased animal costs and allow for Dr. Klein’s continued progress on the research.